Diosmetin alleviates the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma by dually inhibiting angiogenesis and promoting CD8+T cell cytotoxicity - PubMed
4 hours ago
- #Natural Products
- #Immunotherapy
- #Cancer Research
- Diosmetin (DIOS) alleviates immunosuppressive tumor microenvironment (TME) in esophageal squamous cell carcinoma (ESCC).
- DIOS dually inhibits angiogenesis and enhances CD8+T cell cytotoxicity.
- Key contributors to ESCC immunosuppression: angiogenesis and CD8+T cell suppression.
- DIOS suppresses angiogenesis via AURKB/AKT/STAT4/PDGFC axis in ESCC cells and JAK1/STAT1/PDGFC pathway in HUVECs.
- High PDGFC linked to poor prognosis and limited immune checkpoint blockade efficacy in ESCC patients.
- DIOS promotes T cell adhesion, migration, and CD8+T cell killing capacity.
- Combination of DIOS with anti-PD-1 antibody enhances anti-tumor efficacy without significant kidney toxicity.
- Study provides a novel strategy for low-toxicity immunotherapy combinations using natural products.